Review on ABCC10, with data on DNA/RNA, on the protein encoded and where the gene is implicated.
Description
The gene encompasses 23065 bases.
Transcription
Transcript is 744 bps, and has 10 splice variants. In normal tissue A study of the ABCC10 promoter revealed that the presence of E2F and Sp1 sites are required for maximum transcription. In addition other elements were found in the promoter including: cAMP-responsive element binding protein, estrogen receptor binding site, hepatic nuclear factor, progesterone receptor binding site, and sterol regulatory element binding protein (Dabrowska and Sirotnak, 2004) . ABCC10 transcript is widespread at low levels (Hopper et al., 2001; Maher et al., 2005) with highest expression in the pancreas. Decreased expression is observed in activated resting T and B cells (Takayanagi et al., 2004) .
In cancer
In cell lines: In terms of cancer, the ABCC10 gene is expressed in human tumor cell lines, HepG2, CWR22RV1 and TSU-PR1 at greater or equal levels than ABCC1, ABCC2 and ABCC3. Novel ABCC10 transcripts have been identified in HepG2, and CWR22RV1 cells. These transcripts are heterogeneic and imply complexity in the exons and introns of this region (Dabrowska and Sirotnak, 2004) . In breast cancer: ABCC10 transcript is upregulated in breast tumors treated with 5-fluorouracil, anthracycline, cyclophosphamide or taxane based neoadjuvant chemotherapy in comparison with normal tissue. Further, ABCC10 transcript expression is associated with ER positive breast cancer (Hlavac et al., 2013) . In acute myeloid leukemia: ABCC10 transcript is also expressed in acute myeloid leukemia (Hu et al., 2011) . In hepatocellular carcinoma: Transcripts from ABCC10 and various other transporters including: ABCB6, ABCC1, ABCC4, ABCC5, and ABCC12 are upregulated in over 50% hepatocellular carcinoma in untreated patients. It was also observed that microRNA let-7a/e is able to downregulate ABCC10 transcript (Borel et al., 2012) .
Protein

Description
Unglycosylated ABCC10 is ~158 kDa (Hopper et al., 2001 ). ABCC10, like ABCC1, 2, 3 and 6 (see figure above A) has an N-terminal membrane spanning domain (MSD) that is not present in ABCC4, 5, 11 or 12 (figure above B). All ABCC subfamily members contain two Nucleotide Binding Domains (NBD).
Expression
ABCC10 has been detected in various human occular-absorption barrier tissues including, the iris ciliary body, corneal epithelium, conjuntive epithelium, and retina (Chen et al., 2013) . ABCC10 is expressed in cell lines derived from acute myeloid leukemia (Hu et al., 2011) .
Localisation
Localizes basolaterally in ABCC10-transfected LLC-pK1 cells (Malofeeva et al., 2012) .
Function
In vitro ABCC10 transports estrogen β glucuronide, and exhibits modest transport of leukotrienes. Similar to other subfamily members ABCC10 can efflux lipophilic anions (Chen et al., 2003) . ABCC10 is a drug efflux pump that is able to mediate transport of taxanes in vivo. In vitro studies have shown that ABCC10 confers resistance to a variety of hydrophobic drugs, including paclitaxel, docetaxel, vincristine, vinblastine, epothilone B, cytarabine, in a glutathione independent manner (Hopper-Borge et al., 2004; Hopper-Borge et al., 2009) . Prior work has shown that ABCC10 may have a role in natural killer cell mediated lysis. A report demonstrated that a peptide derived from ABCC10 binds to HLA-E and inhibits NK cell-mediated lysis in a CD94 and class I-dependent fashion (Wooden et al., 2005) . ABCC10 ATPase activity is stimulated by estradiol glucuronide, leukotriene, tamoxifen, docetaxel and ARA-C (Malofeeva et al., 2012) . In vivo Abcc10 protects thymus, spleen and bone marrow when exposed to paclitaxel in vivo. Abcc10 loss promotes loss of white blood cells, increased weight loss and increased lethality in mice exposed to high doses of paclitaxel (HopperBorge et al., 2011).
Homology
ABCC10 exhibits structural and/or functional homology with other ABC transporters: CFTR, ABCC1, ABCC2, ABCC3, ABCC6. However, ABCC10 shares the lowest amino acid identity (33.8%) to ABCC1 compared to ABCC2, ABCC3, ABCC4, ABCC5 and ABCC6 (Hopper et al., 2001) . ABCC10 is present in many species including: drosophila melanogaster, xenopus, saccharomyces cerevisiae, danio rerio, sus scrofa, mus musculus, latimeria chalumnae, felis catus, bos taurus, tetranychus urticae (Schippert et al., 2008; Dermauw et al., 2013) . ABCC10 is present in all placental mammals, similar to other subfamily members, ABCC1, ABCC3, ABCC4-7, and ABCC9 (Moitra and Dean, 2011) .
Implicated in
Non small cell lung cancer
Note
In vitro cellular resistance in non small cell lung cancer. ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in nonsmall cell lung cancer (Oguri et al., 2008) . ABCC10/MRP7 expression is associated with vinorelbine resistance in non-small cell lung cancer (Bessho et al., 2009) . Another study implicated ABCC10 in gemcitabine resistance mechanisms in non small cell carcinoma cell lines (Ikeda et al., 2011) . ABCC10 is overexpressed in NSCLC. The expression of ABCC10 in adenocarcinoma is higher than in squamous cell carcinoma. ABCC10 expression in adenocarcinoma correlates with pathological grades and TNM stages (Wang et al., 2009 ).
Head and neck cancer
Note Multidrug resistance protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines (Naramoto et al., 2007) .
Ovarian cancer
Note
A ovarian carcinoma xenograft model demonstrated that intermittant docetaxel dosing of tumors promotes upregulation of MRP7 and other drug resistance genes including btubulin III, Akt2, and thioredoxin. However, when the dosing was continuous the various resistance genes did not upregulate (De Souza et al., 2011) .
Acute myeloid leukemia
Note ABCC10 may play a role in Ara-C resistance mechanisms in acute myeloid leukemia (Hu et al., 2011) . ABCC10 transcript is more highly expressed in childhood AML than in many normal samples (Steinbach et al., 2006) .
Breast cancer
Note
In metastatic breast cancer, a difference in progression-free survival (PFS) was found between circulating stem cells (CTCs) positive and CTCsnegative patients. PFS was shorter in patients whose CTCs expressed two or more ABCC subfamilies, including ABCC10 (Gradilone et al., 2011) . ABCC10 expression may confer therapeutic resistance in solid breast tumors (submitted, Domanitskaya et al.) .
Colorectal cancer
Note
An inverse correlation between ABCC10 transcript and tumor aggressiveness and tumor grade severity was found in colorectal cancer (Hlavata et al., 2012) .
Human immunodeficiency virus
Note ABCC10 polymorphisms contribute to the development of kidney tubular dysfunction (KTD) in some HIV patients (Giacomet et al., 2013) . ABCC10 polymorphisms modulate blood levels of the anti HIV drugs tenofivir, and nevapirine (Pushpakom et al., 2011; Liptrott et al., 2012) .
